Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

Neuropharmacology

Volumn 62, Issue 3, 2012, Pages 1473-1483

  Fell, Matthew J ^a   McKinzie, David L ^a   Monn, James A ^a   Svensson, Kjell A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Glutamate; LY2140023; mGlu2 positive allosteric modulator; mGlu2 3 receptor agonist; Schizophrenia

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; DOPAMINE 2 RECEPTOR; EGLUMETAD; GLUTAMIC ACID; LORAZEPAM; LY 314582; LY 487379; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; N (4' CYANO BIPHENYL 3 YL) N (3 PYRIDINYLMETHYL) ETHANE SULFONAMIDE; N 4 (2 METHOXYPHENOXY)PHENYL N (2,2,2 TRIFLUOROETHYLSULFONYL)PYRID 3 YLMETHYLAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; POMAGLUMETAD METHIONIL; TALAGLUMETAD; UNCLASSIFIED DRUG;

ACUTE DISEASE; AMNESIA; ANIMAL BEHAVIOR; CHOLINERGIC TRANSMISSION; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; CREATINE KINASE BLOOD LEVEL; DISEASE MODEL; DRUG EFFECT; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; HEADACHE; HUMAN; INSOMNIA; LOW DRUG DOSE; METABOTROPIC GLUTAMATE RECEPTOR 3 GENE; MOOD DISORDER; MOTOR DYSFUNCTION; MUTATOR GENE; NAUSEA; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

ALLOSTERIC REGULATION; ANIMALS; EXCITATORY AMINO ACID AGONISTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84856097892     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.06.007     Document Type: Review

References (128)

1. G.K. Aghajanian, and G.J. Marek Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells Neuropharmacology 36 1997 589 599 (Pubitemid 27272104)
2. G.K. Aghajanian, and G.J. Marek Serotonin and hallucinogens Neuropsychopharmacology 21 1999 16S 23S (Pubitemid 29396466)
3. S. Akbarian, N.J. Sucher, D. Bradley, A. Tafazzoli, D. Trinh, W.P. Hetrick, S.G. Potkin, C.A. Sandman, W.E. Bunney Jr.; and E.G. Jones Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics J. Neurosci. 16 1996 19 30 (Pubitemid 26010694)
4. D.B. Allison, J.L. Mentore, M. Heo, L.P. Chandler, J.C. Cappelleri, M.C. Infante, and P.J. Weiden Antipsychotic-induced weight gain: a comprehensive research synthesis Am. J. Psychiatry 156 1999 1686 1696 (Pubitemid 29517559)
5. N.C. Andreasen, and W.T. Carpenter Jr. Diagnosis and classification of schizophrenia Schizophr. Bull. 19 1993 199 214 (Pubitemid 23183145)
6. E. Aronica, J.A. Gorter, H. Ijlst-Keizers, A.J. Rozemuller, B. Yankaya, S. Leenstra, and D. Troost Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins Eur. J. Neurosci. 17 2003 2106 2118 (Pubitemid 36713971)
7. A. Auclair, S. Cotecchia, J. Glowinski, and J.P. Tassin D-amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release J. Neurosci. 22 2002 9150 9154 (Pubitemid 35356155)
8. J.M. Aultman, and B. Moghaddam Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task Psychopharmacology (Berl.) 153 2001 353 364 (Pubitemid 32125820)
9. M.A. Benneyworth, Z. Xiang, R.L. Smith, E.E. Garcia, P.J. Conn, and E. Sanders-Bush A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis Mol. Pharmacol. 72 2007 477 484 (Pubitemid 47124127)
10. J.R. Bishop, V.L. Ellingrod, J. Moline, and D. Miller Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment Schizophr. Res. 77 2005 253 260 (Pubitemid 41112218)
11. J. Boyle, L. Trick, S. Soo-ampon, S. Lilley, L. Levine, and I. Hindmarch Evaluation of the cognitive and psychomotor profile of a novel anxiolytic, LY544344, compared to lorazepam in normal volunteers Eur. Neuropsychopharmacol. 13 2003 S365 S375
12. E.J. Brnardic, M.E. Fraley, R.M. Garbaccio, M.E. Layton, J.M. Sanders, C. Culberson, M.A. Jacobson, B.C. Magliaro, P.H. Hutson, J.A. O'Brien, S.L. Huszar, J.M. Uslaner, K.L. Fillgrove, C. Tang, Y. Kuo, S.M. Sur, and G.D. Hartman 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: hit-to-lead efforts Bioorg. Med. Chem. Lett. 20 2010 3129 3133
13. E.J. Bromet, and S. Fennig Epidemiology and natural history of schizophrenia Biol. Psychiatry 46 1999 871 881 (Pubitemid 29452978)
14. V. Bruno, G. Battaglia, A. Copani, M. D'Onofrio, P. Di Iorio, A. De Blasi, D. Melchiorri, P.J. Flor, and F. Nicoletti Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs J. Cereb. Blood Flow Metab. 21 2001 1013 1033 (Pubitemid 32823739)
15. F.P. Bymaster, D.O. Calligaro, J.F. Falcone, R.D. Marsh, N.A. Moore, N.C. Tye, P. Seeman, and D.T. Wong Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96 (Pubitemid 26053226)
16. J. Cartmell, J.A. Monn, and D.D. Schoepp The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats J. Pharmacol. Exp. Ther. 291 1999 161 170 (Pubitemid 29451586)
17. J. Cartmell, J.A. Monn, and D.D. Schoepp Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine Psychopharmacology (Berl.) 148 2000 423 429 (Pubitemid 30169761)
18. J. Cartmell, J.A. Monn, and D.D. Schoepp The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing Eur. J. Pharmacol. 400 2000 221 224 (Pubitemid 30438730)
19. J. Cartmell, K.W. Perry, C.R. Salhoff, J.A. Monn, and D.D. Schoepp The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat J. Neurochem. 75 2000 1147 1154 (Pubitemid 30660504)
20. J. Cartmell, K.W. Perry, C.R. Salhoff, J.A. Monn, and D.D. Schoepp Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade Neuropharmacology 40 2001 847 855 (Pubitemid 32510798)
21. J. Cartmell, and D.D. Schoepp Regulation of neurotransmitter release by metabotropic glutamate receptors J. Neurochem. 75 2000 889 907 (Pubitemid 30660476)
22. Q. Chen, G. He, S. Wu, Y. Xu, G. Feng, Y. Li, L. Wang, and L. He A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population Schizophr. Res. 73 2005 21 26 (Pubitemid 39574674)
23. S.Y. Cherlyn, P.S. Woon, J.J. Liu, W.Y. Ong, G.C. Tsai, and K. Sim Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance Neurosci. Biobehav. Rev. 34 2010 958 977
24. P.J. Conn, and J.P. Pin Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37 1997 205 237 (Pubitemid 27238875)
25. C. Corti, G. Battaglia, G. Molinaro, B. Riozzi, A. Pittaluga, M. Corsi, M. Mugnaini, F. Nicoletti, and V. Bruno The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection J. Neurosci. 27 2007 8297 8308 (Pubitemid 47219630)
26. C. Corti, L. Crepaldi, S. Mion, A.L. Roth, J.H. Xuereb, and F. Ferraguti Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia Biol. Psychiatry 62 2007 747 755 (Pubitemid 47374649)
27. J.T. Coyle Glutamate and schizophrenia: beyond the dopamine hypothesis Cell Mol. Neurobiol. 26 2006 365 384
28. W. Danysz, U. Essmann, I. Bresink, and R. Wilke Glutamate antagonists have different effects on spontaneous locomotor activity in rats Pharmacol. Biochem. Behav. 48 1994 111 118 (Pubitemid 24135163)
29. W. Danysz, J.T. Wroblewski, and E. Costa Learning impairment in rats by N-methyl-d-aspartate receptor antagonists Neuropharmacology 27 1988 653 656
30. S. Dedeurwaerdere, C. Wintmolders, R. Straetemans, D. Pemberton, and X. Langlois Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist Psychopharmacology (Berl) 214 2010 505 514
31. E. Doumazane, P. Scholler, J.M. Zwier, E. Trinquet, P. Rondard, and J.P. Pin A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors FASEB J 1 2011 66 77
32. E. Dunayevich, J. Erickson, L. Levine, R. Landbloom, D.D. Schoepp, and G.D. Tollefson Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder Neuropsychopharmacology 33 2008 1603 1610 (Pubitemid 351684700)
33. G.E. Duncan, S. Miyamoto, J.N. Leipzig, and J.A. Lieberman Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine Brain Res. 843 1999 171 183 (Pubitemid 29488707)
34. G.E. Duncan, S.S. Moy, D.J. Knapp, R.A. Mueller, and G.R. Breese Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia Brain Res. 787 1998 181 190 (Pubitemid 28197904)
35. M.F. Egan, R.E. Straub, T.E. Goldberg, I. Yakub, J.H. Callicott, A.R. Hariri, V.S. Mattay, A. Bertolino, T.M. Hyde, C. Shannon-Weickert, M. Akil, J. Crook, R.K. Vakkalanka, R. Balkissoon, R.A. Gibbs, J.E. Kleinman, and D.R. Weinberger Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia Proc. Natl. Acad. Sci. U.S.A. 101 2004 12604 12609 (Pubitemid 39122071)
36. B.A. Ellenbroek Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs Pharmacol. Ther. 57 1993 1 78 (Pubitemid 23130739)
37. M.J. Fell, B.G. Johnson, K.A. Svensson, and D.D. Schoepp Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039 J. Pharmacol. Exp. Ther. 326 2008 209 231
38. M.J. Fell, J.S. Katner, B.G. Johnson, A. Khilevich, J.M. Schkeryantz, K.W. Perry, and K.A. Svensson Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge Neuropharmacology 58 2010 632 639
39. M.J. Fell, K.W. Perry, J.F. Falcone, B.G. Johnson, V.N. Barth, K.S. Rash, V.L. Lucaites, P.G. Threlkeld, J.A. Monn, D.L. McKinzie, G.J. Marek, K.A. Svensson, and D.L. Nelson In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6- dicarboxylic acid (LY379268) J. Pharmacol. Exp. Ther. 331 2009 1126 1136
40. M.E. Fraley Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia Expert. Opin. Ther. Pat. 19 2009 1259 1275
41. R. Freedman Schizophrenia N. Engl. J. Med. 349 2003 1738 1749 (Pubitemid 37315012)
42. Y. Fujii, H. Shibata, R. Kikuta, C. Makino, A. Tani, N. Hirata, A. Shibata, H. Ninomiya, N. Tashiro, and Y. Fukumaki Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia Psychiatr. Genet. 13 2003 71 76 (Pubitemid 36724534)
43. R. Galici, N.G. Echemendia, A.L. Rodriguez, and P.J. Conn A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity J. Pharmacol. Exp. Ther. 315 2005 1181 1187 (Pubitemid 41635406)
44. R. Galici, C.K. Jones, K. Hemstapat, Y. Nong, N.G. Echemendia, L.C. Williams, T. de Paulis, and P.J. Conn Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice J. Pharmacol. Exp. Ther. 318 2006 173 185
45. X.M. Gao, K. Sakai, R.C. Roberts, R.R. Conley, B. Dean, and C.A. Tamminga Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia Am. J. Psychiatry 157 2000 1141 1149 (Pubitemid 30432497)
46. R.M. Garbaccio, E.J. Brnardic, M.E. Fraley, G.D. Hartman, P.H. Hutson, J.A. O'Brien, B.C. Magliaro, J.M. Uslaner, S.L. Huszar, K.L. Fillgrove, J.H. Small, C. Tang, Y. Kuo, and M.A. Jacobson Discovery of oxazolobenzimidazoles as positive allosteric modulators for the mGluR2 receptor ACS Med. Chem. Lett. 1 2010 406 410
47. J.C. Gewirtz, and G.J. Marek Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors Neuropsychopharmacology 23 2000 569 576
48. S. Ghose, R. Chin, A. Gallegos, R. Roberts, J. Coyle, and C. Tamminga Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia Schizophr. Res. 111 2009 131 137
49. J. Gonzalez-Maeso, R.L. Ang, T. Yuen, P. Chan, N.V. Weisstaub, J.F. Lopez-Gimenez, M. Zhou, Y. Okawa, L.F. Callado, G. Milligan, J.A. Gingrich, M. Filizola, J.J. Meana, and S.C. Sealfon Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 2008 93 97 (Pubitemid 351355090)
50. A. Gozzi, C.H. Large, A. Schwarz, S. Bertani, V. Crestan, and A. Bifone Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine Neuropsychopharmacology 33 2008 1690 1703 (Pubitemid 351684709)
51. B. Greco, R.W. Invernizzi, and M. Carli Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268 Psychopharmacology (Berl.) 179 2005 68 76 (Pubitemid 40576693)
52. C. Grillon, J. Cordova, L.R. Levine, and C.A. Morgan 3rd Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans Psychopharmacology (Berl.) 168 2003 446 454 (Pubitemid 36994028)
53. A.J. Gruber, G.G. Calhoon, I. Shusterman, G. Schoenbaum, M.R. Roesch, and P. O'Donnell More is less: a disinhibited prefrontal cortex impairs cognitive flexibility J. Neurosci. 30 2010 17102 17110
54. G. Gu, D.S. Lorrain, H. Wei, R.L. Cole, X. Zhang, L.P. Daggett, H.J. Schaffhauser, L.J. Bristow, and S.M. Lechner Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition Brain Res. 1197 2008 47 62
55. D.S. Gupta, R.E. McCullumsmith, M. Beneyto, V. Haroutunian, K.L. Davis, and J.H. Meador-Woodruff Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia Synapse 57 2005 123 131 (Pubitemid 41023469)
56. E.A. Hackler, N.E. Byun, C.K. Jones, J.M. Williams, R. Baheza, S. Sengupta, M.D. Grier, M. Avison, P.J. Conn, and J.C. Gore Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation Neuroscience 168 2010 209 218
57. C.G. Hahn, H.Y. Wang, D.S. Cho, K. Talbot, R.E. Gur, W.H. Berrettini, K. Bakshi, J. Kamins, K.E. Borgmann-Winter, S.J. Siegel, R.J. Gallop, and S.E. Arnold Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia Nat. Med. 12 2006 824 828 (Pubitemid 44050073)
58. S. Harich, G. Gross, and A. Bespalov Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment Psychopharmacology (Berl.) 192 2007 511 519 (Pubitemid 46870746)
59. G.A. Higgins, T.M. Ballard, J.N. Kew, J.G. Richards, J.A. Kemp, G. Adam, T. Woltering, S. Nakanishi, and V. Mutel Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent Neuropharmacology 46 2004 907 917 (Pubitemid 38471944)
60. H.H. Holcomb, A.C. Lahti, D.R. Medoff, T. Cullen, and C.A. Tamminga Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia Neuropsychopharmacology 30 2005 2275 2282 (Pubitemid 41643980)
61. H. Homayoun, M.E. Jackson, and B. Moghaddam Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats J. Neurophysiol. 93 2005 1989 2001 (Pubitemid 40404399)
62. H. Homayoun, and B. Moghaddam Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors Cereb. Cortex 16 2006 93 105 (Pubitemid 41748285)
63. G. Imre The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268 CNS Drug Rev. 13 2007 444 464 (Pubitemid 350233471)
64. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am. J. Psychiatry 148 1991 1301 1308
65. M.P. Johnson, D. Barda, T.C. Britton, R. Emkey, W.J. Hornback, G.E. Jagdmann, D.L. McKinzie, E.S. Nisenbaum, J.P. Tizzano, and D.D. Schoepp Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) Psychopharmacology (Berl.) 179 2005 271 283 (Pubitemid 40576715)
66. C.A. Jones, A.M. Brown, D.P. Auer, and K.C. Fone The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat Psychopharmacology (Berl.) 2010 (Epub ahead of print)
67. J.S. Kim, H.H. Kornhuber, W. Schmid-Burgk, and B. Holzmuller Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia Neurosci. Lett. 20 1980 379 382 (Pubitemid 11160082)
68. B.J. Kinon, L. Zhang, J.E. Williams, O.O. Osuntokun, B.A. Millen, and S. Kollack-Walker LY2140023 Monohydrate: an agonist at the mGlu2/3 receptor for the treatment of schizophrenia Schizophr. Res. 117 2010 379 389
69. A. Klodzinska, M. Bijak, K. Tokarski, and A. Pilc Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice Pharmacol. Biochem. Behav. 73 2002 327 332 (Pubitemid 34765571)
70. J.H. Krystal, W. Abi-Saab, E. Perry, D.C. D'Souza, N. Liu, R. Gueorguieva, L. McDougall, T. Hunsberger, A. Belger, L. Levine, and A. Breier Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects Psychopharmacology (Berl.) 179 2005 303 309 (Pubitemid 40576718)
71. J.H. Krystal, A. Belger, C. D'Souza, A. Anand, D.S. Charney, G.K. Aghajanian, and B. Moghaddam Therapeutic implications of the hyperglutamatergic effects of NMAD antagonists Neuropsychopharmacology 22 1999
72. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr.; and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214 (Pubitemid 24081509)
73. A.C. Lahti, H.H. Holcomb, X.M. Gao, and C.A. Tamminga NMDA-sensitive glutamate antagonism: a human model of psychosis Neuropsychopharmacology 22 1999 S158 S169
74. A.J. Law, and J.F. Deakin Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses Neuroreport 12 2001 2971 2974 (Pubitemid 32882018)
75. J.E. Lisman, J.T. Coyle, R.W. Green, D.C. Javitt, F.M. Benes, S. Heckers, and A.A. Grace Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia Trends Neurosci. 31 2008 234 242
76. D.S. Lorrain, C.S. Baccei, L.J. Bristow, J.J. Anderson, and M.A. Varney Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 Neuroscience 117 2003 697 706 (Pubitemid 36263162)
77. D.S. Lorrain, H. Schaffhauser, U.C. Campbell, C.S. Baccei, L.D. Correa, B. Rowe, D.E. Rodriguez, J.J. Anderson, M.A. Varney, A.B. Pinkerton, J.M. Vernier, and L.J. Bristow Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge Neuropsychopharmacology 28 2003 1622 1632 (Pubitemid 41070863)
78. D.S. Lorrain, C.S. Baccei, L.D. Correa, and L.J. Bristow Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels Neuropharmacology 48 2005 927 935 (Pubitemid 40602600)
79. G.J. Marek Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition Eur. J. Pharmacol. 639 2010 81 90
80. G.J. Marek, R.A. Wright, B.G. Johnson, K.A. Svensson, M. Benvenga, S. Chaney, D.D. Schoepp, and J. Monn Activation of mGlu2 receptors mediates the "antipsychotic-like" activity of mGlu2/3 receptor agonists in three psychotomimetic drug models and regional distribution of mGlu2 vs mGlu3 receptors Neuropharmacology 55 2008 608
81. G.J. Marek, R.A. Wright, D.D. Schoepp, J.A. Monn, and G.K. Aghajanian Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex J. Pharmacol. Exp. Ther. 292 2000 76 87 (Pubitemid 30026356)
82. M.J. Marino, and P.J. Conn Direct and indirect modulation of the N-methyl d-aspartate receptor Curr. Drug Targets CNS Neurol. Disord. 1 2002 1 16
83. D. Michelson, L.R.D. Levine, P. Mesters, D.D. Schoepp, E. Dunayevich, and G. Tollefson Clinical studies with mGluR2/3 agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Proceedings and abstracts of the 5th international meeting on metabotropic glutamate receptors Neuropharmacology 49 Suppl. 1 2005 257
84. S. Miyamoto, G.E. Duncan, C.E. Marx, and J.A. Lieberman Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol. Psychiatry 10 2005 79 104 (Pubitemid 40139590)
85. B. Moghaddam, B. Adams, A. Verma, and D. Daly Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J. Neurosci. 17 1997 2921 2927 (Pubitemid 27155025)
86. B. Moghaddam, and B.W. Adams Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 281 1998 1349 1352 (Pubitemid 28406826)
87. J.A. Monn, S.M. Massey, M.J. Valli, S.S. Henry, G.A. Stephenson, M. Bures, M. Herin, J. Catlow, D. Giera, R.A. Wright, B.G. Johnson, S.L. Andis, A. Kingston, and D.D. Schoepp Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6- dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors J. Med. Chem. 50 2007 233 240 (Pubitemid 46147704)
88. J.A. Monn, M.J. Valli, B.G. Johnson, C.R. Salhoff, R.A. Wright, T. Howe, A. Bond, D. Lodge, L.A. Spangle, J.W. Paschal, J.B. Campbell, K. Griffey, J.P. Tizzano, and D.D. Schoepp Synthesis of the four isomers of 4-aminopyrrolidine-2, 4-dicarboxylate: identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase J. Med. Chem. 39 1996 2990 3000 (Pubitemid 26251037)
89. J.A. Monn, M.J. Valli, S.M. Massey, M.M. Hansen, T.J. Kress, J.P. Wepsiec, A.R. Harkness, J.L. Grutsch Jr.; R.A. Wright, B.G. Johnson, S.L. Andis, A. Kingston, R. Tomlinson, R. Lewis, K.R. Griffey, J.P. Tizzano, and D.D. Schoepp Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors J. Med. Chem. 42 1999 1027 1040 (Pubitemid 29153432)
90. J.A. Monn, M.J. Valli, S.M. Massey, R.A. Wright, C.R. Salhoff, B.G. Johnson, T. Howe, C.A. Alt, G.A. Rhodes, R.L. Robey, K.R. Griffey, J.P. Tizzano, M.J. Kallman, D.R. Helton, and D.D. Schoepp Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6- dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties J. Med. Chem. 40 1997 528 537 (Pubitemid 27080033)
91. A. Nakazato, T. Kumagai, K. Sakagami, R. Yoshikawa, Y. Suzuki, S. Chaki, H. Ito, T. Taguchi, S. Nakanishi, and S. Okuyama Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists J. Med. Chem. 43 2000 4893 4909 (Pubitemid 32002702)
92. F. Nicoletti, V. Bruno, A. Copani, G. Casabona, and T. Knopfel Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 19 1996 267 271 (Pubitemid 26000672)
93. A. Nikiforuk, P. Popik, K.U. Drescher, M.M. van Gaalen, A.L. Relo, M. Mezler, G. Marek, H. Schoemaker, G. Gross, and A. Bespalov Effects of a positive allosteric modulator of mGlu2 receptors LY487379 on cognitive flexibility and impulsive-like responding in rats J. Pharmacol. Exp. Ther. 2010
94. C.M. Niswender, and P.J. Conn Metabotropic glutamate receptors: physiology, pharmacology, and disease Annu. Rev. Pharmacol. Toxicol. 50 2010 295 322
95. H. Ohishi, R. Shigemoto, S. Nakanishi, and N. Mizuno Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat Neuroscience 53 1993 1009 1018 (Pubitemid 23126097)
96. H. Ohishi, R. Shigemoto, S. Nakanishi, and N. Mizuno Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study J. Comp. Neurol. 335 1993 252 266 (Pubitemid 23256191)
97. J.W. Olney, and N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch. Gen. Psychiatry 52 1995 998 1007
98. J.W. Olney, J.W. Newcomer, and N.B. Farber NMDA receptor hypofunction model of schizophrenia J. Psychiatr. Res. 33 1999 523 533
99. J. Parada-Turska, and W.A. Turski Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks Neuropharmacology 29 1990 1111 1116
100. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat. Med. 13 2007 1102 1107 (Pubitemid 47517511)
101. A.L. Pehrson, and B. Moghaddam Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion Psychopharmacology (Berl.) 211 2010 443 455
102. R.S. Petralia, Y.X. Wang, A.S. Niedzielski, and R.J. Wenthold The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations Neuroscience 71 1996 949 976 (Pubitemid 26090013)
103. L.S. Pilowsky, R.A. Bressan, J.M. Stone, K. Erlandsson, R.S. Mulligan, J.H. Krystal, and P.J. Ell First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients Mol. Psychiatry 11 2006 118 119 (Pubitemid 43164609)
104. L.M. Rorick-Kehn, B.G. Johnson, J.L. Burkey, R.A. Wright, D.O. Calligaro, G.J. Marek, E.S. Nisenbaum, J.T. Catlow, A.E. Kingston, D.D. Giera, M.F. Herin, J.A. Monn, D.L. McKinzie, and D.D. Schoepp Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4- amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039) J. Pharmacol. Exp. Ther. 321 2007 308 317 (Pubitemid 46456992)
105. L.M. Rorick-Kehn, B.G. Johnson, K.M. Knitowski, C.R. Salhoff, J.M. Witkin, K.W. Perry, K.I. Griffey, J.P. Tizzano, J.A. Monn, D.L. McKinzie, and D.D. Schoepp In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders Psychopharmacology (Berl.) 193 2007 121 136 (Pubitemid 46906627)
106. B.L. Roth, S.C. Craigo, M.S. Choudhary, A. Uluer, F.J. Monsma Jr.; Y. Shen, H.Y. Meltzer, and D.R. Sibley Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors J. Pharmacol. Exp. Ther. 268 1994 1403 1410 (Pubitemid 24100360)
107. B.A. Rowe, H. Schaffhauser, S. Morales, L.S. Lubbers, C. Bonnefous, T.M. Kamenecka, J. McQuiston, and L.P. Daggett Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site J. Pharmacol. Exp. Ther. 326 2008 240 251 (Pubitemid 351872147)
108. H. Schaffhauser, B.A. Rowe, S. Morales, L.E. Chavez-Noriega, R. Yin, C. Jachec, S.P. Rao, G. Bain, A.B. Pinkerton, J.M. Vernier, L.J. Bristow, M.A. Varney, and L.P. Daggett Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2 Mol. Pharmacol. 64 2003 798 810 (Pubitemid 37153048)
109. C. Schlumberger, D. Schafer, C. Barberi, L. More, J. Nagel, M. Pietraszek, W.J. Schmidt, and W. Danysz Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition Behav. Pharmacol. 20 2009 56 66
110. D.D. Schoepp Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system J. Pharmacol. Exp. Ther. 299 2001 12 20 (Pubitemid 32905113)
111. D.D. Schoepp, D.E. Jane, and J.A. Monn Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacology 38 1999 1431 1476 (Pubitemid 29457728)
112. R. Schreiber, D. Lowe, A. Voerste, and J. De Vry LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine Eur. J. Pharmacol. 388 2000 R3 R4
113. P. Seeman Glutamate agonists for schizophrenia stimulate dopamine D2High receptors Schizophr. Res. 99 2008 373 374
114. P. Seeman, C. Caruso, and M. Lasaga Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268 Synapse 62 2008 154 158
115. P. Seeman, and H.C. Guan Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor Synapse 63 2009 935 939
116. S. Spinelli, T. Ballard, S. Gatti-McArthur, G.J. Richards, M. Kapps, T. Woltering, J. Wichmann, H. Stadler, J. Feldon, and C.R. Pryce Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys Psychopharmacology (Berl.) 179 2005 292 302 (Pubitemid 40576717)
117. W.P.J.M. Spooren, F. Gasparini, H. van der Putten, M. Koller, S. Nakanishi, and R. Kuhn Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice Eur. J. Pharmacol. 397 2000 R1
118. K.A. Svensson The mGlu2 Receptor as a novel drug target Schizophr. Res. 117 2010 114
119. C.J. Swanson, and D.D. Schoepp A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists Ann. N.Y. Acad. Sci. 1003 2003 309 317 (Pubitemid 38083064)
120. M.T. Taber, and H.C. Fibiger Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors J. Neurosci. 15 1995 3896 3904
121. G. Tsai, and J.T. Coyle Glutamatergic mechanisms in schizophrenia Annu. Rev. Pharmacol. Toxicol. 42 2002 165 179 (Pubitemid 34160524)
122. J.M. Uslaner, S.M. Smith, S.L. Huszar, R. Pachmerhiwala, R.M. Hinchliffe, J.D. Vardigan, and P.H. Hutson Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants Psychopharmacology (Berl.) 206 2009 641 651
123. D.R. Weinberger Schizophrenia drug says goodbye to dopamine Nat. Med. 13 2007 1018 1019 (Pubitemid 47517494)
124. M.L. Woolley, D.J. Pemberton, S. Bate, C. Corti, and D.N. Jones The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity Psychopharmacology (Berl.) 196 2008 431 440
125. R.A. Wright, M.B. Arnold, W.J. Wheeler, P.L. Ornstein, and D.D. Schoepp [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain J. Pharmacol. Exp. Ther. 298 2001 453 460 (Pubitemid 32673394)
126. X.P. Zeng, F. Le, and E. Richelson Muscarinic m4 receptor activation by some atypical antipsychotic drugs Eur. J. Pharmacol. 321 1997 349 354 (Pubitemid 27105938)
127. Y. Zhai, C.A. George, J. Zhai, E.S. Nisenbaum, M.P. Johnson, and L.K. Nisenbaum Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex Neuropsychopharmacology 28 2003 45 52
128. J.R. Zysk, D. Widzowski, L.A. Sygowski, K.S. Knappenberger, N. Spear, C.S. Elmore, P. Dorff, H. Liu, J. Doherty, and V. Chhajlani Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268 Synapse 2010